Onconetix shares surge 19.91% on Realbotix robot delivery to Ericsson amid pending acquisition.

Thursday, Apr 9, 2026 2:28 pm ET1min read
ONCO--
Onconetix Inc. surged 19.91% in intraday trading following a press release highlighting Realbotix's delivery of its first Vinci-equipped humanoid robot to Ericsson. The announcement reinforces the strategic value of Realbotix, a pending acquisition target for Onconetix, by showcasing the commercial viability of its patented AI vision technology capable of real-time engagement tracking. Investors appear to view the successful deployment as validation of the anticipated all-stock merger, which is expected to close in the second half of 2026, thereby boosting confidence in Onconetix's pivot toward AI-driven medical technology solutions.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet